Program
Alveltamig
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine · Prostatic Neoplasms, led by 2 companies.
Furthest: phase 3, since Sep 16, 202511 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 1)
☆ TrackCompare Suzhou Zelgen Biopharmaceuticals and Hansoh Pharmaceutical Group →Its drug page, every study →
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals | 1010 open or running | phase 3since Sep 16, 2025 | Jul 28, 2023 | Dec 2026phase 1 · NCT06592638 |
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Aug 13, 2026 | Aug 13, 2026 | Sep 15, 2028phase 1 · NCT07892625 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2023First study: phase 2 study in Small Cell Lung CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT05978284 · 54 planned · China
- Feb 21, 2024Phase 2 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06283719 · 265 planned · China
- May 28, 2024Phase 2 study in Carcinoma, NeuroendocrineSuzhou Zelgen Biopharmaceuticals · NCT06440057 · 78 planned · China
- Sep 9, 2024Phase 1 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06592638 · 30 planned · United States
- Jun 9, 20252 phase 2 studiesSuzhou Zelgen Biopharmaceuticals · NCT07024277, NCT07038096
- Sep 16, 2025Phase 3 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07189455 · 420 planned · China
- Nov 13, 2025Phase 1 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07231445 · 100 planned · China
- Nov 20, 2025Phase 2 study in Solid TumorSuzhou Zelgen Biopharmaceuticals · NCT07258121 · 400 planned · China
- May 13, 2026Phase 3 study in Carcinoma, NeuroendocrineSuzhou Zelgen Biopharmaceuticals · NCT07595913 · 240 planned · China
- Aug 13, 2026Hansoh Pharmaceutical Group's first study: phase 1 study in Small Cell Lung CarcinomaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT07892625 · 338 planned
- Oct 19, 2026Primary completion moved from 2026-04 to 2027-04Date moved laterphase 2 · +12 months · NCT06283719
Ahead
- Dec 2026Primary completion: phase 1 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06592638
- Apr 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT06283719
- Sep 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07038096
- Dec 2027Primary completion: phase 2 study in Neuroendocrine Prostate CancerSuzhou Zelgen Biopharmaceuticals · NCT07024277
TargetBeta
“A trispecific T-cell engaging (TCE) antibody directed against two different epitopes of the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tarlatamabrule | Amgen | phase 3 | 13 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| gocatamig | Merck | phase 3 | 4 |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| HLX3901 | Fosun Pharma | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07892625Small Cell Lung Carcinoma | 1 | Not yet recruiting | Hansoh Pharmaceutical Group | Sep 15, 2028 | 338 |
| NCT07595913Carcinoma, Neuroendocrine · China | 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals | Jun 2028 | 240 |
| NCT07258121Solid Tumor · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2028 | 400 |
| NCT07231445Small Cell Lung Carcinoma · China | 1 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2028 | 100 |
| NCT07189455Small Cell Lung Carcinoma · China | 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Oct 2028 | 420 |
| NCT07038096Small Cell Lung Carcinoma · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Sep 2027 | 350 |
| NCT07024277Neuroendocrine Prostate Cancer · China | 2 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2027 | 60 |
| NCT06592638Small Cell Lung Carcinoma · United States | 1 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2026 | 30 |
| NCT06440057Carcinoma, Neuroendocrine · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | May 2026 | 78 |
| NCT06283719Small Cell Lung Carcinoma · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Apr 2027 | 265 |
| NCT05978284Small Cell Lung Carcinoma · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Sep 2026 | 54 |
How it is read
Names in the registry
- “ZG006”, 11 entries
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 7 studies
- Carcinoma, Neuroendocrine, 2 studies
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.